VenoVision

VenoVision non-invasively provides the advanced cardiac monitoring needed to better personalize therapy for millions of heart failure and at-risk patients in the hospital and home in an underserved $33B market. VenoVision uses thermal imaging and ML to deliver central venous pressure and waveform hemodynamic insights - previously limited to implants and catheterizations - enabling deterioration to be spotted sooner and therapy to be guided more closely. With VenoVision's easy-to-use, "point-&-press" device, medical teams can improve patient stability and drive down the billions of dollars spent on avoidable days in the ICU and hospital. We’re proud to be a Delaware C-Corp with Israeli origins! VenoVision was conceptualized in the Hebrew University of Jerusalem’s BioDesign Program and carried out its proof-of-concept clinical trial at Shaare Zedek Medical Center. It won "most innovative" award at M2D2 Impact 2023, it is an alum of MassChallenge (Israel 2021), and it is a Health Wildcatters accelerator (Dallas, Texas) 2022-23 portfolio company.